Spyre Therapeutics (SYRE) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed TG Therapeutics (TGTX) over the past year, gaining 351.9% versus a gain of 49.2%. Over five years, TGTX leads with a +60.1% price change compared with -60.9% for SYRE. TG Therapeutics is the larger company by market cap ($8.38 billion vs $7.77 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SYRE | TGTX |
|---|---|---|
| Share price | $84.19 | $54.72 |
| Market cap | $7.77B | $8.38B |
| 1-day change | +5.37% | +2.59% |
| YTD return | +143.89% | +78.93% |
| 1-year return | +351.92% | +49.20% |
| 5-year return | -60.93% | +60.13% |
| P/E ratio (TTM) | — | 19.90 |
| Forward P/E | — | 20.15 |
| EPS (TTM) | $-1.92 | $2.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $616.29M |
| Revenue growth (YoY) | — | +87.32% |
| Net income (latest FY) | $-155.20M | $447.18M |
| Gross margin | — | 83.66% |
| Operating margin | — | 20.01% |
| Net margin | — | 72.56% |
| 52-week high | $110.18 | $59.30 |
| 52-week low | $18.12 | $26.76 |
| Distance from 52-week high | -23.59% | -7.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +42.78% | +27.39% |
| Average volume | 1.22M | 2.01M |
| Shares outstanding | 92.29M | 153.08M |
| Employees | 125 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed TGTX by 302.7 percentage points over the past year.
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
SYRE vs TGTX FAQ
Which is bigger, Spyre Therapeutics or TG Therapeutics?
TG Therapeutics (TGTX) is larger, with a market capitalization of $8.38B compared with $7.77B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, SYRE or TGTX?
SYRE returned +351.92% over the past 12 months, compared with +49.20% for TGTX (price return, excluding dividends). Past performance does not predict future results.
Are Spyre Therapeutics and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.